Study in Subjects With Moderate Atopic Dermatitis
Open the official record
This page only displays public information reproduced from the official ClinicalTrials.gov record NCT03859986. It adds no medical advice, opinions, or eligibility judgments. The official record remains the source of truth for eligibility criteria, enrollment, and contact information.
All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.
Official title
A Phase 2, Randomized, Double-Blind, Vehicle-Controlled, Parallel-Group Study To Evaluate The Safety And Efficacy Of ALX-101 Topical Gel Administered Twice Daily In Adult And Adolescent Subjects With Moderate Atopic Dermatitis
Brief summary
Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.
This is a Phase 2, randomized, double-blind, vehicle-controlled, parallel-group study to evaluate the safety and efficacy of ALX-101 Gel 5% and a matching ALX-101 Gel Vehicle when applied topically twice daily for 56 days in adult and adolescent subjects with moderate atopic dermatitis
Study identification
- NCT ID
- NCT03859986
- Recruitment status
- Not listed
- Study type
- Interventional
- Phase
- Phase 2
- Enrollment
- 124 participants
Conditions and interventions
Conditions
Eligibility (public fields only)
- Age range
- 12 Years and older
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Mar 8, 2019 (Actual)
- Primary completion
- Jan 2020 (Estimated)
- Completion
- Jan 2020 (Estimated)
- Last update posted
- Nov 5, 2019
2019 – 2020
United States locations
- U.S. sites
- 20
- U.S. states
- 13
- U.S. cities
- 20
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| Ralexar Investigational Site 10 | Beverly Hills | California | 90212 | — |
| Ralexar Investigational Site 5 | Los Angeles | California | 90045 | — |
| Ralexar Investigational Site 3 | Aventura | Florida | 33180 | — |
| Ralexar Investigational Site 2 | Jacksonville | Florida | 32256 | — |
| Ralexar Investigational Site 22 | Miami | Florida | 33147 | — |
| Ralexar Investigational Site 18 | Pinellas Park | Florida | 33781 | — |
| Ralexar Investigational Site 6 | Sanford | Florida | 32771 | — |
| Ralexar Investigational Site 13 | Marietta | Georgia | 30060 | — |
| Ralexar Investigational Site 7 | Boise | Idaho | 83713 | — |
| Ralexar Investigational Site 21 | Gurnee | Illinois | 60031 | — |
| Ralexar Investigational Site 1 | Indianapolis | Indiana | 46250 | — |
| Ralexar Investigational Site 17 | Louisville | Kentucky | 40202 | — |
| Ralexar Investigational Site 12 | Las Vegas | Nevada | 89177 | — |
| Ralexar Investigational Site 14 | Beachwood | Ohio | 44122 | — |
| Ralexar Investigational Site 8 | Fairborn | Ohio | 45324 | — |
| Ralexar Investigational Site 9 | Oklahoma City | Oklahoma | 73118 | — |
| Ralexar Investigational Site 19 | Spartanburg | South Carolina | 29307 | — |
| Ralexar Investigational Site 16 | Austin | Texas | 78745 | — |
| Ralexar Investigational Site 4 | San Antonio | Texas | 78213 | — |
| Ralexar Investigational Site 15 | Seattle | Washington | 98101 | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
Non-U.S. locations
This page focuses on the U.S. directory. The official record also lists 2 non-U.S. sites.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT03859986, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Nov 5, 2019 · Synced Nov 19, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.